Back China Strategy

CHINA: New signals point to faster moves away from Zero-Covid

Published on November 30, 2022

∙ Download the PDF Report

By

Michael Hirson

In our note yesterday we remarked that the zero-Covid strategy is effectively over, and the question now is what replaces it: a cautious “Very Low Covid” strategy (our basecase), a chaotic pivot, or a rapid controlled pivot that starts this winter (please see: China’s strategy is shifting from Zero-Covid to Very Low Covid). Policies, politics (including recent protests) and outbreaks are all highly fluid, so it is important to monitor incremental signals and update the outlook accordingly.

With that backdrop, there were several developments in China on Wednesday that make it more explicitly clear that zero-Covid is over and suggest the leadership is becoming more comfortable with a pivot.

Most important was a forum that vice premier Sun Chunlan held with public health officials. Sun has the day-to-day responsibility for Covid policies, including ensuring compliance with the “dynamic clearing” (zero-Covid) strategy. But the official readout of the meeting showed a significant change in messaging:

  • Sun signaled that China has entered a new – less dangerous – phase of battling Covid due to declining severity of the virus and China’s vaccination campaign: “With the weakening of the pathogenicity of Omicron virus, the popularization of vaccination, and the accumulation of prevention and control experience, China’s epidemic prevention and control is facing a new situation and new tasks.” The emphasis on Omicron being mild is very significant, implying growing confidence on the part of China’s leadership that it can cope with a rise in infections as well efforts to prepare the public for an increase in cases as the country moves from zero-Covid into a new stage.
  • Sun did not mention “dynamic clearing” or repeat standard phrases emphasizing unswerving adherence to the policy. Her overall tone was less political than in the past and emphasized the contributions of public health experts.

There were also signals at the local level in China. Guangzhou, battling China’s largest outbreak, lifted restrictions on movement in districts that are not considered high risk, and will also allow some close contacts of Covid cases to quarantine at home. Beijing, in the midst of its largest outbreak to date, will also allow some close contacts to quarantine at home. These are significant changes.

Encouraging signs – but some key caveats

The economic and especially social pressures on zero-Covid – most dramatically seen in mass protests over the weekend – have forced a faster change in policies than we have been expecting. The key question now is how authorities’ comfort with loosening holds up as cases rise. China is in the very early stages of moving away from zero-Covid, with infections still extremely low by international standards (less than 40K new cases per day as of this week).

We are slightly lowering the probability of our Very Low Covid basecase scenario to 55% (from 60%), raising the probability of a Rapid Controlled Pivot to 30% (from 20%) and lowering the odds of a Chaotic Pivot from 30% to 25%. This reflects the growing confidence behind loosening measures and stepped-up preparations for a pivot. The basecase of Very Low Covid entails containment measures that remain tight overall to slow growth in infections in coming quarters, and a subdued economic recovery over the course of 2023.

We have been guarded about expectations for China’s pace of reopening based on two main factors: (1) the leadership’s determination to keep fatalities and serious illness low; and (2) the significant risks of a surge of illness/death given the incomplete vaccination campaign and vulnerabilities in the public health system. These warnings still apply: we expect the pivot to be cautious, and subject to an ebb-and-flow of tightening and loosening based on public health conditions. No country has executed a smooth pivot on Covid, and Xi Jinping has very strong political incentives to keep deaths very low by international standards.

Key signposts include:

  • Outbreak dynamics. It will be important to watch the course of specific outbreaks (such as Guangzhou and Beijing) but also to monitor whether a more relaxed approach in those cities is seeding outbreaks elsewhere. If so, and cases nationwide show an explosive growth trajectory, we expect a re-tightening of containment measures.
  • Fatality rates. Public pronouncements that cases are not severe are encouraging, but again China is in early days still.
  • Signs that the hospital system is coming under strain as cases rise. This does not appear to be the case yet, but decisions to reduce testing and quarantine announcements are partly an admission that as infections rise, quarantine centers will run out of capacity. Many cities are building large quarantine hospitals, but most of this capacity will not be online until this spring (and even then a shortage of trained personnel will remain a key vulnerability).
  • Further shifts in central government messaging, including from Xi Jinping. This could come at the Central Economic Work Conference (typically held in early-to-mid December) and the Politburo meeting that immediately precedes it.

DISCLOSURES AND DISCLAIMERS

Analyst Certification

The analyst, 22V Research Group, primarily responsible for the preparation of this research report attests to the following: (1) that the views and opinions rendered in this research report reflect his or her personal views about the subject companies or issuers; and (2) that no part of the research analyst’s compensation was, is, or will be directly related to the specific recommendations or views in this research report.

Analyst Certifications and Independence of Research.

Each of the 22V Research analysts whose names appear on the front page of this report hereby certify that all the views expressed in this Report accurately reflect our personal views about any and all of the subject securities or issuers and that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views of in this Report.

22V Research (the “Company”) is an independent research provider. The Company is not a member of the FINRA or the SIPC and is not a registered broker dealer or investment adviser. 22V Research has no other regulated or unregulated business activities which conflict with its provision of independent research.

22V Research, LLC is a professional services and independent publication organization. 22V Research, LLC is not a securities broker-dealer, not a member of the Financial Industry Regulatory Authority (FINRA), not a registered investment advisor (RIA) and not a member of SIPC.

Securities transactions, when offered, are offered by 22V Securities, LLC through LPS Capital, LLC. Certain employees of 22V Securities, LLC are dually registered as securities representatives of LPS Capital, LLC or Analyst Hub Securities, LLC. 22V Securities, LPS Capital and Analyst Hub Securities are members FINRA, SIPC.

https://brokercheck.finra.org/

Current Ratings Definition.

SECTOR OUTPERFORM: An “outperform” rating anticipates the company will outperform the S&P Regional Banking Index (peer group).

SECTOR PERFORM: A “market perform” rating anticipates the company will perform in line with the S&P Regional Banking Index (peer group).

SECTOR UNDERPERFORM: An “underperform” rating anticipates the company will underperform the S&P Regional Banking Index (peer group).

Limitation Of Research And Information.

This Report has been prepared for distribution to only qualified institutional or professional clients of 22V Research Group. The contents of this Report represent the views, opinions, and analyses of its authors. The information contained herein does not constitute financial, legal, tax or any other advice. All third-party data presented herein were obtained from publicly available sources which are believed to be reliable; however, the Company makes no warranty, express or implied, concerning the accuracy or completeness of such information. In no event shall the Company be responsible or liable for the correctness of, or update to, any such material or for any damage or lost opportunities resulting from use of this data. Nothing contained in this Report or any distribution by the Company should be construed as any offer to sell, or any solicitation of an offer to buy, any security or investment. Any research or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of an overall portfolio strategy and you should consult with a professional financial advisor, legal and tax advisor prior to making any investment decision. 22V Research Group shall not be liable for any direct or indirect, incidental or consequential loss or damage (including loss of profits, revenue or goodwill) arising from any investment decisions based on information or research obtained from 22V Research Group.

Reproduction And Distribution Strictly Prohibited.

No user of this Report may reproduce, modify, copy, distribute, sell, resell, transmit, transfer, license, assign or publish the Report itself or any information contained therein. Notwithstanding the foregoing, clients with access to working models are permitted to alter or modify the information contained therein, provided that it is solely for such client’s own use. This Report is not intended to be available or distributed for any purpose that would be deemed unlawful or otherwise prohibited by any local, state, national or international laws or regulations or would otherwise subject the Company to registration or regulation of any kind within such jurisdiction.

Copyrights, Trademarks, Intellectual Property.

22V Research Group, and any logos or marks included in this Report are proprietary materials. The use of such terms and logos and marks without the express written consent of 22V Research Group is strictly prohibited. The copyright in the pages or in the screens of the Report, and in the information and material therein, is proprietary material owned by 22V Research Group unless otherwise indicated. The unauthorized use of any material on this Report may violate numerous statutes, regulations and laws, including, but not limited to, copyright, trademark, trade secret or patent laws.